- Revenue: Not reported in QQ2 2025 (revenue field null in the income statement).
- Gross profit: Not disclosed due to absence of reported revenue (grossProfit is null).
- Operating income: -213,382 for QQ2 2025, representing a QoQ improvement of approximately 26.6% and a YoY improvement of about 51.3%, but still a material loss.
- Net income: -430,183 for QQ2 2025, down 21.4% QoQ but up 26.3% YoY in terms of loss magnitude (net income negative both periods).
- EPS: -32.23 for QQ2 2025, up about 88.8% QoQ and 96.9% YoY in terms of loss magnitude per share.
- EBITDA: -306,908; EBITDA margin unavailable (negative earnings environment common for preclinical biotech).
- Cash flow: Operating cash flow of -6,271; Free cash flow also -6,271; net cash provided by financing activities +79,816; forex impact -68,180; net change in cash +5,365; cash at end of period: 14,633.
- Balance sheet highlights: Total assets 78,533; total liabilities 4,237,292; total stockholders’ equity -4,158,759 (negative equity).
- Liquidity: Current ratio 0.00433; quick ratio 0.00433; cash ratio 0.00352, indicating extreme liquidity constraints.
- Debt: Total debt 1,209,031; net debt 1,194,398; substantial financing dependency implied by negative equity and limited operating cash flow.
- Share count: Weighted average shares outstanding 1,334,600,000; EPS diluted -32.23.